[Infantile psychosis, pseudo-Alzheimer syndrome, and trisomy 21. A trial of treatment with folinic acid: preliminary report].
Trisomy 21 produces excess sensibility to methotrexate (dihydrofolate reductase inhibitor). A trial of medication with folinic acid (5-formyl-tetrahydrofolate) was realized on 39 trisomic 21 patients. 30 of them were affected by severe infantile psychosis and the other 9 were affected by a severe Alzheimer-like regression. On 69 assays, 37 were favorable and 32 were null. A dose/effect correlation was highly significant. It is proposed that a systematic investigation of the effects of folinic acid (associated or not with monocarbon precursors) be studied in cases of trisomy 21 complicated by precocious psychosis or severe secondary regression.
Lejeune
J
J
Rethoré
M O
MO
de Blois
M C
MC
Peeters
M
M
D000293:Adolescent; D000328:Adult; D000544:Alzheimer Disease / Q000188:drug therapy / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004314:Down Syndrome / Q000150:complications*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology
Psychose infantile, syndrome pseudo-Alzheimer, et trisomie 21. Essai de médication par l'acide folinique: rapport préliminaire.